V VIVA
DEAD

Serial Number

86857807

Owner

Viva Pharmaceutical Inc.

Attorney

Gina Lupino

Filing Date

Dec 26, 2015

Add to watchlist:

No watchlists yet
View on USPTO

V VIVA Trademark

Serial Number: 86857807

V VIVA is a trademark filed by Viva Pharmaceutical Inc. on December 26, 2015. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Viva Pharmaceutical Inc. (3 trademarks)

13880 Viking Place
Richmond, B.C. V6V1K8 , CA

Entity Type: 03

Trademark Details

Filing Date

December 26, 2015

Registration Date

Not Registered

Goods & Services

Skin emollient preparations, hair care preparations and skin care preparations, namely, dermatologicals, antibiotic tissue healants, anti-inflammatory and antibacterial ointments, corticosteroid ointments and creams, antiinfective ointments and creams, scabicides; anti-viral ointments and creams; full line of pharmaceutical preparations and substances, namely, pharmaceutical preparations and substances for the treatment, alleviation and/or prevention of gastro-intestinal disorders, disorders of the central nervous system, disorders of the respiratory system, heart conditions and other disorders of the cardiovascular system, and migraines and other forms of headache; analgesics; antivirals; anaesthetics; anti-infectives; anti-inflammatories; antibiotics; antidepressants; broncho-dilators; anti-cancer preparations; medicated lotions for the skin and hair; decongestants and anti-histamines; muscle relaxants; anti-emetics; immunosuppressive agents; antispasmodic agents, antiepileptic agents; cardiotonics; scabicides; anti-malarials; cough suppressants; cough and cold preparations; expectorants; anti-leukemic agents; anti-arrhythmics; dermatologicals; tissue healants; lung surfactants; vasopressors; ophthalmic and optic agents; antitumour agents; antidotes to digitalis poisoning; preparations for treatment of digoxin and digitoxin intoxication; antineoplastic agents; antiprotozoal agents; nondepolarizing skeletal neuromuscular blocking agents; preparations for treatment of gout; xanthine oxidase inhibitors; preparations for cessation of smoking; preparations for treatment of Parkinson's disease; preparations for treatment of hypothyroidism; full line of nutraceutical preparations and substances, namely, extracts or isolates from plant, alga, fungus, non-human animal material, bacterium (including spirulina and non-living, e.g. tyndallized bacteria), namely, enzymes, vitamins, minerals, amino acids, essential fatty acids, synthetic duplicates, probiotics, homeopathic medicines; probiotics, namely, acidophilus, bifidobacterium and lactobacillus; vitamin compounds, namely, vitamin supplements, vitamins, multi-vitamins, vitamin compounds with minerals, vitamin compounds with iron; mineral preparations, namely, minerals; nutritional, dietary and herbal supplements and herbal preparations, namely, semen platycladi, radix polygalae, indole-3-carbionol, 5-hydroxy-L-tryptophan, echinacea, bilberry, cascara sagrada, celery seed, cranberry, nettle root, uva ursi, dandelion root, devil's claw, feverfew, ginger root, ginkgo biloba, grapeseed, resveratrol, citrus bioflavonoids, green tea, hawthorn, horse chestnut, milk thistle, olive leaf, panax ginseng, saw palmetto, siberian ginseng, silica, St. John's Wort, valerian, lutein, zeaxanthin, cayenne, hawaiian spirulina, swedish bitters; fatty supplements, namely, flax seed oil and fish derived oils; glucosamine, chondroitin, methyl-sulfonyl-methane, whey, creatine; herbal products, namely, herbals; standardized herbal extracts, namely, semen platycladi, radix polygalae, echinacea, bilberry, cascara sagrada, celery seed, cranberry, nettle root, uva ursi, dandelion root, devil's claw, feverfew, ginger root, ginkgo biloba, grapeseed, green tea, hawthorn, horse chestnut, milk thistle, olive leaf, panax ginseng, saw palmetto, siberian ginseng, silica, St. John's Wort, valerian, lutein, zeaxanthin, cayenne, hawaiian spirulina, swedish bitters; nutraceuticals, namely, dietary supplements and herbal products, namely, folic acid, lutein, zeaxanthin, lycopene, acidophilus, bee pollen, beta-carotene, bromelain, choline, flavonoids, grape seed extract, kelp, lecithin, lipoic acid, mushroom extracts, SAM-e, crustacean exoskeleton, soy protein, spirulina; amino acid compounds, namely, NAC (n-acetyl cysteine) and L-glutamine; sports nutrition products, namely, whey proteins and creatines; antioxidants, namely, vitamins C and E, vitamin A, beta-carotene, selenium and carotenoids; cosmeceuticals, namely, medicinal herbal creams, lotions and oils for treatment of skin damage and repair; food products, namely, herbs, greens, dehydrated foods derived from plants, namely, vegetable and fruit powder, vegetable protein and greens, natural flavors derived from fruits, dietary fiber; evening primrose oil, salmon oil, whey, creatine; nutritional products and natural health products, namely, carotenoids, enzymes, alfalfa leaf, conjugated linoleic acid, apple cider vinegar, fenugreek seed, coenzyme Q10, alpha lipoic acid, pine bark extract, crustacean exoskeleton, garlic, kelp, pectin, policosanol, flaxseed oil, pumpkin seed oil, borage oil, perilla seed oil, salmon oil, evening primrose oil, tuna oil, thyme oil, peppermint oil complex, lecithin, phosphatidyl choline, soya lecithin granules, phosphatidyl serine, bee pollen, bee propolis, royal jelly, soy isoflavones complex, chasteberry, echinacea

Skin cleansing lotions; skin clarifiers and skin masks

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 10, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 10, 2021 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Aug 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Aug 20, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 28, 2020 CRFA
ASSIGNED TO LIE
Jul 21, 2020 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 14, 2020 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 17, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 17, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 17, 2020 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 6, 2020 RCCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 1, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 1, 2019 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 20, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 20, 2019 GNSL
SUSPENSION LETTER WRITTEN
Jun 20, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2019 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 11, 2019 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 14, 2018 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 14, 2018 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 14, 2018 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 29, 2018 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 29, 2018 GNS3
LETTER OF SUSPENSION E-MAILED
May 29, 2018 GNSL
SUSPENSION LETTER WRITTEN
May 29, 2018 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 8, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 8, 2018 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 7, 2018 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 7, 2017 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 7, 2017 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 7, 2017 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 17, 2017 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 3, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
May 3, 2017 GNSL
SUSPENSION LETTER WRITTEN
May 3, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 1, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 1, 2017 CRFA
ASSIGNED TO LIE
Apr 28, 2017 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 20, 2017 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 20, 2017 TCCA
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 27, 2016 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 27, 2016 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 27, 2016 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 21, 2016 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 19, 2016 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 19, 2016 GNSL
SUSPENSION LETTER WRITTEN
Apr 19, 2016 CNSL
ASSIGNED TO EXAMINER
Apr 12, 2016 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jan 29, 2016 AMPX
ASSIGNED TO LIE
Jan 21, 2016 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 7, 2016 PARI
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 6, 2016 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 5, 2016 NWOS
NEW APPLICATION ENTERED
Dec 30, 2015 NWAP